Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513019 · ClinicalTrials.gov registry record · Phase 2
Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation
A Phase 2 study of Dermatillomania and Neurotic Excoriation, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00513019: Completed Phase 2 study of Dermatillomania and Neurotic Excoriation, sponsored by University of Chicago.
NCT00513019 is a Phase 2 study of Dermatillomania and Neurotic Excoriation that has completed, run by University of Chicago. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513019, a Phase 2 study of Dermatillomania and Neurotic Excoriation, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested is that Lamictal (lamotrigine) will be more effective than placebo in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.
Primary Outcome
The Yale-Brown Obsessive Compulsive Scale Modified for Neurotic Excoriation (NE-YBOCS) was the primary outcome measure - severity of illness. The NE-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lamictal (lamotrigine)
Study Locations (1)
Minnesota
- Ambulatory Research Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00513019 record still lists
NCT00513019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Dermatillomania appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00513019 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00513019 about?
NCT00513019 is a clinical study titled "Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation". The goal of the proposed study is to evaluate the comparative efficacy of Lamictal (lamotrigine) to placebo in neurotic excoriation. Thirty subjects with neurotic excoriation will receive 12 weeks of double-blind treatment with Lamictal (lamotrigine) or matching placebo. The hypothesis to be tested ...
What is the current status of trial NCT00513019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2007-08. Estimated completion is 2009-09.
What conditions does trial NCT00513019 study?
This clinical trial studies the following conditions: Dermatillomania, Neurotic Excoriation, Pathologic Skin Picking, Psychogenic Excoriation.
What interventions are being tested in trial NCT00513019?
The interventions under investigation include: Placebo (DRUG), Lamictal (lamotrigine) (DRUG).
Who is sponsoring clinical trial NCT00513019?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00513019 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatillomania
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00513019's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia